Abstract
Editors' Note: Commenting on “Pearls & Oy-sters: Tacrolimus neurotoxicity presenting as an isolated brainstem lesion,” Dr. Chang wonders whether the patient reported had, in fact, posterior reversible encephalopathy syndrome (PRES) rather than a direct neurotoxic effect of tacrolimus. Drs. Saadi and Schmahmann, authors of the article, explain that the patient's blood pressure was within the normal range throughout hospitalization, making PRES unlikely. Critiquing “Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis,” Dr. Kantor comments that the Class I evidence of safety/tolerability is incorrect because the trial was not powered to demonstrate such an effect, and because of differences in urine calcium:creatinine ratio, incidence of nausea, and hypercalcemia between the 2 groups. Sotirchos et al., authors of the article, disagree with these …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
